BIVI (BioVie) Quarterly EPS earnings growth

BioVie Inc. (BIVI) maintains a high scientific standing in the therapy of neurodegeneration and liver pathologies. Patents for the treatment of chronic ailments ensure future revenue from intellectual property rights. Stable management focuses on drug trials, where the latest mark stands at 30.80. The quarterly EPS growth trend clearly demonstrates the real efficiency of capital value generation and hidden business risks.

biovieinc.com (BIVI) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 11/15/2026

Summary analytical data breakdowns for BioVie (BIVI)

- share price and consensus valuation forecast:

Stock Quotes BioVie Inc|BIVI - Price Target Chart

- business market valuation indicators:

Market Capitalization BioVie Pharma|BIVI - Total Enterprise Value

- balance sheet net asset value indicators:

Net Assets per Single Share BioVie|BIVI - Accounting Value of Company|Market Capitalization to Book Value Ratio biovieinc.com|BIVI - Aggregate Company Assets

- company liabilities and liquidity data:

- earnings and market multiples details:

BIVI - Company Net Income|Future Profit BioVie Inc.|BIVI - Company Value to Net Income|Forward P/E Multiple BioVie Inc.|BIVI - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BioVie Inc|BIVI - Operating profit before amortization|Net earnings per share (EPS TTM) BioVie|BIVI - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months biovieinc.com|BIVI - Expected net earnings per share growth this year|Earnings growth forecast for next year BioVie Inc.

- sales revenue and business income indicators:

BIVI - Company Revenue|Projected Sales Volume BioVie Inc.|BIVI - Price-to-Revenue Coefficient|Forward Price-to-Revenue Multiple BioVie

Comprehensive company analysis:BioVie Inc., BIVI

The development of BioVie Inc. (BIVI) depends directly on the outcomes of clinical trials for drugs targeting cirrhosis and Alzheimer's disease. An analysis of quarter-over-quarter EPS dynamics reflects changes in net income per share, accounting for tax adjustments and subsidies, allowing for the timely detection of a systemic decline in business efficiency and the avoidance of capital freezes amidst high R&D risk volatility.

Direct competitors

ARWR (Arrowhead Pharmaceuticals Inc) - Year-over-year net earnings per share growth for the last 12 months|MIRM (Mirum Pharma) - Year-over-year earnings per share growth for the last twelve months|DVAX (Dynavax Corp) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months arbutusbio.com ABUS|Quarterly EPS earnings growth IVA|GYRE (Gyre Therapeutics) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ASMB (Assembly Bio)|Net earnings per share growth for the trailing year Galectin|Genfit Corp - Quarterly EPS earnings growth|DRRX - Quarterly EPS earnings growth|ALGS: Quarterly EPS earnings growth|GLMD (Galmed Pharma) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last twelve months ENDRA|hepionpharma.com (HEPA) - Year-over-year net earnings per share change for the last twelve months